Company: NDRA
Filing Date: 2025-10-15
Form Type: 8-K/A
Source: 0001654954-25-011825
Chunk: 1

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-15
Form: 8-K/A
Chunk 1
---
-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory note:This amendment amends the Current Report on Form 8-K filed by the registrant on October 15, 2025 (the “Original Filing”). This amendment is being filed solely to correct a technical error (i.e., an inadvertent failure to properly code Items 1.01, 1,02, 3.02, 5.08, 7.01 and 8.01 in the EDGAR submission page for the Original Filing). No text from the Original Filing or its exhibits has been altered other than to incorporate herein by reference the exhibits to the Original Filing.

Item 1.01 Entry into a Material Definitive Agreement.

Securities Purchase Agreement

On October 10, 2025, ENDRA Life Sciences Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Purchasers”) pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement offering (the “Offering”) an aggregate of 744,340 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), and/or prefunded warrants in lieu thereof (the “Prefunded Warrants”), and warrants (the “Common Warrants”) to purchase an aggregate of up to 1,488,680 shares of Common Stock at a per share exercise price of $6.32. Each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrants were sold at a combined purchase price of $6.57. In accordance with the rules of the Nasdaq Stock Market, a member of the Company’s board of directors who participated in the Offering (the “Director Participant”) purchased Shares and Common Warrants at a combined purchase price of $7.06 and was issued Common Warrants with an exercise price of $6.81.

The Offering is expected to close on October 15, 2025 (the “Closing Date”). The gross proceeds of the Offering are expected to be